AXSM logo

AXSM
Axsome Therapeutics Inc

11,792
Mkt Cap
$9.14B
Volume
363,961.00
52W High
$191.50
52W Low
$86.99
PE Ratio
-38.77
AXSM Fundamentals
Price
$181.21
Prev Close
$182.94
Open
$183.35
50D MA
$168.89
Beta
0.74
Avg. Volume
767,322.80
EPS (Annual)
-$5.99
P/B
123.65
Rev/Employee
$564,704.25
$3,941.58
Loading...
Loading...
News
all
press releases
Factors You Need to Know Ahead of ProPetro's Q4 Earnings Release
PUMP heads into Q4 earnings with revenues expected to fall 11.6% year over year and estimates calling for a 13-cent loss.
Zacks·23h ago
News Placeholder
More News
News Placeholder
Should You Buy Axsome Therapeutics Stock Before Feb. 23?
Key PointsAxsome got a big boost late last year after regulators granted priority review for its Alzheimer's drug...
Nasdaq News: Markets·9d ago
News Placeholder
Principal Financial Group Inc. Acquires 12,923 Shares of Axsome Therapeutics, Inc. $AXSM
Principal Financial Group Inc. grew its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 3.6% in the third quarter, according to its most recent disclosure with the...
MarketBeat·9d ago
News Placeholder
Axsome Therapeutics (NASDAQ:AXSM) Given New $245.00 Price Target at Jefferies Financial Group
Jefferies Financial Group boosted their price objective on Axsome Therapeutics from $200.00 to $245.00 and gave the company a "buy" rating in a report on Tuesday...
MarketBeat·11d ago
News Placeholder
Axsome Therapeutics (NASDAQ:AXSM) CEO Herriot Tabuteau Sells 32,410 Shares
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) CEO Herriot Tabuteau sold 32,410 shares of Axsome Therapeutics stock in a transaction that occurred on Monday, February 2nd. The stock was...
MarketBeat·11d ago
News Placeholder
Leerink Partners Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price
Leerink Partners upped their price objective on Axsome Therapeutics from $150.00 to $205.00 and gave the company an "outperform" rating in a research report on Wednesday...
MarketBeat·17d ago
News Placeholder
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026?
Axsome's Auvelity delivered robust 2025 sales growth. A pending FDA decision in 2026 could unlock a broader market and drive sales further.
Zacks·19d ago
News Placeholder
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Axsome Therapeutics, Inc. $AXSM
Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 30.7% during the 3rd quarter, according to the company in its...
MarketBeat·19d ago
News Placeholder
Cabot Wealth Management Inc. Buys Shares of 5,560 Axsome Therapeutics, Inc. $AXSM
Cabot Wealth Management Inc. purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 3rd quarter, according to its most recent 13F filing with the...
MarketBeat·19d ago
News Placeholder
FY2025 Earnings Forecast for AXSM Issued By HC Wainwright
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of Axsome Therapeutics in a research note issued on...
MarketBeat·23d ago
<
1
2
...
>

Latest AXSM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.